英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

downgrade    音标拼音: [d'ɑʊngr'ed]
n. 下坡
a.
ad. 下坡的

下坡下坡的

downgrade
n 1: the property possessed by a slope or surface that descends
v 1: rate lower; lower in value or esteem [ant: {upgrade}]

149 Moby Thesaurus words for "downgrade":
abase, abridge, adown, aslant, aslantwise, aslope, at a slant,
atilt, atrophy, belittle, below, break, bump, bust, cascade,
cataract, chute, collapse, comedown, compress, crash, curtail, cut,
cut back, cut down, damp, dampen, debacle, debase, decadence,
declension, declination, decline, declined, declining, declivate,
declivitous, declivity, declivous, decrease, decry, deduct,
deflate, defluxion, degeneracy, degeneration, degrade, demerit,
demote, denigrate, deplume, depose, depreciate, depress,
descending, descension, descent, dethrone, devalue, devolution,
diminish, dip, dipping, disenfranchise, disfranchise, disgrade,
disparage, displace, displume, dispossess, down, down south,
downbend, downcome, downcurve, downfall, downflow, downgate,
downhill, downline, downplay, downpour, downright, downrush,
downstairs, downstream, downstreet, downtown, downtrend, downturn,
downward, downward trend, downwards, downwith, drop, dropping,
fall, falling, falling off, falling-off, grade, gradient,
gravitation, hang, hanging, humble, inclination, lessen, lower,
mark down, minimize, off plumb, on the downgrade, on the skids,
on the wane, pare, play down, plummeting, pounce, rakingly, rapids,
reduce, retrench, roll back, run down, scale down, shorten,
simplify, slantingly, slantways, slantwise, slaunchways, slipping,
slopeways, slopingly, step down, stoop, strip of rank, swoop,
take from, tipsily, tune down, undervalue, upgrade, uphill, waning,
waterfall, write down, write off


请选择你想看的字典辞典：
单词字典翻译
downgrade查看　downgrade　在百度字典中的解释百度英翻中〔查看〕
downgrade查看　downgrade　在Google字典中的解释Google英翻中〔查看〕
downgrade查看　downgrade　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Ibrutinib improves diffuse large B-cell lymphoma survival
    NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
  • Ibrutinib Resistance Mechanisms and Treatment Strategies for . . .
    BTK is a central contributor to B-cell lymphoma pathogenesis, as it is significantly more active (increased phosphorylation) in B-cell lymphomas than in normal B-cells Additionally, BTK plays a fundamental role in modulating chemokine and integrin signaling (CXCR4), thereby regulating B-cell trafficking and tissue homing [ 7 ]
  • Imbruvica (Ibrutinib) | Lymphoma News Today
    A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
  • CLL and SLL Treatment | IMBRUVICA® (ibrutinib)
    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
  • Ibrutinib improves survival for younger people with diffuse . . .
    “This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
  • Official Healthcare Professional Website | IMBRUVICA . . .
    Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA ® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8%, and grade 3 or 4 anemia in 2 8%, based on laboratory measurements Monitor complete blood counts monthly
  • Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
    Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
  • Your Guide to Your IMBRUVICA (ibrutinib) Treatment Plan
    IMBRUVICA® may cause serious side effects, including: Infections can happen during treatment with IMBRUVICA® These infections can be serious and may lead to death Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA® B cell BTK
  • Imbruvica (Ibrutinib): First Drug Approved for the Treatment . . .
    In 2013, ibrutinib received accelerated approval for the treatment of patients with mantle-cell lymphoma who had received at least 1 previous therapy 10 In 2014, ibrutinib was approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who received at least 1 previous regimen, and for patients with CLL with the 17p deletion 10
  • Ibrutinib as a treatment of hematologic autoimmune disorders . . .
    Autoimmune manifestations associated with B‐cell lymphomas are a well‐known and frequent event, with an incidence rate of 4%–8% based mostly on retrospective series 1, 2, 3 Such manifestations can occur at any time during the course of the disease, either before B‐cell lymphoma onset, at the time of diagnosis or even several years
  • IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the . . .
    Dreyling, et al Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell
  • U. S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment . . .
    Marginal zone lymphoma (MZL) is a slow-growing B-cell lymphoma arising from white blood cells (lymphocytes) at the edges of lymphoid tissue 3 MZL accounts for approximately 8% of all cases of non-Hodgkin's lymphoma in adults, and the median age of diagnosis is 65 years old 3,4 There are three sub-types of MZL: mucosa-associated lymphoid





中文字典-英文字典  2005-2009